Palvella Therapeutics reports strong Phase 2 results for QTORIN rapamycin gel
Share
Palvella’s (NASDAQ:PVLA) topical rapamycin gel improved lesions in most patients and showed a favorable safety profile, supporting upcoming FDA discussions on Breakthrough designation and Phase 3 development.
